Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trypan blue-assisted vitrectomy.

Brendan J Vote1, Matthew K Russell, Brian C Joondeph

  • 1Department of Ophthalmology, University of Auckland, Auckland, New Zealand.

Retina (Philadelphia, Pa.)
|October 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pivotal Trial Toward Effectiveness of Self-administered OCT in Neovascular Age-related Macular Degeneration. Report 2-Artificial Intelligence Analytics.

Ophthalmology science·2025
Same author

Evaluation of the Efficiency of a Digital Workflow for Cataract Planning in Patients with Astigmatism.

Clinical ophthalmology (Auckland, N.Z.)·2024
Same author

Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study.

EClinicalMedicine·2023
Same author

Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice.

International journal of retina and vitreous·2023
Same author

Identifying Genetic Biomarkers Predicting Response to Anti-Vascular Endothelial Growth Factor Injections in Diabetic Macular Edema.

International journal of molecular sciences·2022
Same author

A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration.

American journal of ophthalmology·2022
Same journal

Persistent placoid maculopathy: long term outcomes and prognostic factors.

Retina (Philadelphia, Pa.)·2026
Same journal

ANTI-VEGF THERAPY SWITCHING RETINAL DISEASES: Characterizing Clinical Manifestations and Common Involved Genes: ERRATUM.

Retina (Philadelphia, Pa.)·2026
Same journal

THE EFFICACY AND SAFETY OF SUBRETINAL BALANCED SALT SOLUTION INJECTION IN DIABETIC MACULAR EDEMA WITH HARD EXUDATES: ERRATUM.

Retina (Philadelphia, Pa.)·2026
Same journal

EVALUATING CLINICAL OUTCOMES OF AMNIOTIC MEMBRANE COVERAGE COMBINED WITH EARLY VITRECTOMY IN THE MANAGEMENT OF PERFORATING GLOBE INJURIES.

Retina (Philadelphia, Pa.)·2026
Same journal

Mid-Phase Hyperfluorescent Plaques as a biomarker of disease activity in Central Serous Chorioretinopathy: Clinical Course and Treatment Response - MICRoN report number Ten.

Retina (Philadelphia, Pa.)·2026
Same journal

Severe retinal non-perfusion is associated with fewer retinal lesions on ultra-wide field fundus photography in proliferative diabetic retinopathy.

Retina (Philadelphia, Pa.)·2026
See all related articles

Trypan blue dye effectively stains and aids in removing internal limiting membrane, epiretinal membranes, and posterior hyaloid during vitrectomy. This staining enhances surgical efficiency and safety without causing retinal toxicity.

Area of Science:

  • Ophthalmology
  • Surgical Innovation
  • Retinal Surgery

Background:

  • Epiretinal membranes and internal limiting membranes can complicate vitrectomy.
  • Accurate visualization and removal of these tissues are crucial for successful surgical outcomes.

Purpose of the Study:

  • To assess the effectiveness of trypan blue dye in staining and facilitating the removal of intraocular membranes during pars plana vitrectomy.
  • To evaluate the safety and efficacy of trypan blue as a surgical adjunct.

Main Methods:

  • Retrospective review of 26 eyes undergoing vitrectomy with trypan blue staining.
  • Analysis of diagnoses including epiretinal membrane, macular hole, and proliferative vitreoretinopathy.
  • Assessment of intraoperative visualization and postoperative visual acuity and retinal toxicity.

Related Experiment Videos

Main Results:

  • Trypan blue provided consistent bluish staining, aiding identification and removal of target membranes in all cases.
  • Visual acuity improved or remained stable in 21 out of 26 patients six months post-surgery.
  • No clinical signs of retinal toxicity were observed in any of the patients.

Conclusions:

  • Trypan blue staining is a valuable tool in vitreoretinal surgery.
  • It enhances the identification and removal of internal limiting membrane, epiretinal membranes, and posterior hyaloid.
  • The dye improves surgical efficiency and safety without adverse effects.